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Background: To analyze the experience of completion pneumonectomy for lung cancer at a single institution
in China.
Methods: From January 1988 to December 2007, 92 patients underwent completion pneumonectomy for the
treatment of lung cancer. The indications were second primary lung cancer (n = 51), Local metastasis (n = 37) and
Lung metastasis (n = 4). The median interval between the primary operation and CP was 24.4 months (1.5-145 m).
Results: There was no intraoperative deaths. The CP procedure lasted 4.3 h (1.5-8 h). Blood loss in the CP
performance was 1854.5 ml (200-9100 ml) 9 (9.78%) patients died in the postoperative period: pulmonary
embolism (n = 2), disseminated intravascular coagulation (DIC) after the multisystem failure (n = 1), respiratory
failure after contralateral pneumonia (n = 5), bronchopleural fistula (BPF) with acute respiratory distress
syndrome (ARDS) (n = 1) 31(33.7%) patients had at least one major nonfatal complication. The 1, 3 and 5 year
survival rates were 81%, 26% and 14% respectively.
Conclusions: Completion pneumonectomy for lung cancer is a safe surgical procedure for the skilled surgeon
though it has a relatively higher complications and the long-term survival is acceptable.
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Completion Pneumonectomy is defined as the procedure
to remove the reminder of the lung partially resected
during a pervious operation [1]. When compared to
standard pneumonectomy, it is a more challenging tech-
nical procedure associated with reported increased
operative mortality and morbidity [2]. The indications
for completion pneumonectomy include both benign
and malignant diseases [3]. Indications for malignant
disease have increased quickly with regard to the
increasing frequency of lung cancer, the widespread use
of limited resection for some early stage lung cancer and
the increasing demands for pulmonary resection for pul-
monary metastases. Indications for malignancies include
local recurrence after prior lobectomy, second primary
tumors, recurrent metastases from tumors in other
systems or carcinoma occurring after previous lobectomy* Correspondence: xiaozhou@hotmail.com; JGNWP@yahoo.com.cn
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reproduction in any medium, provided the or(or local resection) done for benign disease [1]. In this
paper, we review our experience with this procedure for
the treatment of lung cancer (CP for benign disease not
being considered here) and to evaluate the postoperative
outcomes and long-term results of it.Methods
Definitions and inclusion criteria
The primary operation was defined as the first ipisilat-
eral operation to move the lung tissue (eg lobectomy or
bilobectomy or wedge resection). Hospital mortality
included all intraoperative and postoperative deaths dur-
ing hospitalization or within 30 days after the completion
pneumonectomy but the patients were discharged earlier.
Recurrent lung cancer and second primary lung cancer
were discriminated using the following criteria proposed
by Martini and colleagues [4]: a second primary tumor
was of different histology or if histology was the same,
the disease-free interval between cancer was at least
2 years or the second cancer was in the different
lobe but with no cancer in common lymphatic ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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its origin could be clearly traced to a carcinoma in situ.Table 2 Factors associated with CP mortality






Heavy smoker ns nsPatients
From January 1988 to December 2007, 92 patients
underwent CP for the treatment of lung cancer at a
single academic institution, which accounted for 4.5% of
all pneumonectomy during the same period.
There were 83 male and 9 female patients. Mean age
at the time of completion pneumonectomy was 57 years
(32-71yo).There were 17 patients who underwent the
primary operations at other hospitals.
The patients study variables included the following:
age, sex, obesity (body mass index >27), smoking history,
the indications for the primary operation and for CP,
hypertention( systolic pressure >140 mmHg or dia-
stolic pressure >90 mmHg or if the patient had already
been treated for hypertention), pulmonary function,
neoadjuvant treatment, interval between the primary
operation and CP, TNM stage, the operative finding in
CP, surgical procedure, operative mortality and long
term survival. Written informed consent was obtained
from the patient for publication of this report and any
accompanying images.
The indications for the primary operation and for CP
are showed as the Table 1.
The 88 patients for lung cancer were sarcomatoid lung
cancer (n = 1), small cell lung cancer (n = 2), squamous
cell carcinoma (n = 46), adenocarcinoma (n = 29), ade-
nosquamous carcinoma (n = 14). The 4 patients for be-
nign disease: Tuberculosis (n = 3) and Bronchietasis
(n = 1). The primary operation was lobectomy (n = 57),
sleeve lobectomy (n = 15), lobectomy extended to the
chest wall (n = 2) ,bilobectomy (n = 6) and segmentect-
omy (n = 12) and 15 patients were done the primary op-
eration by VATS(video-assisted thoracic surgery). The
non-small cell lung cancer had the TNM stage as the
following: stage I (n = 53), stage II (n = 26), stage IIIa
(n = 6), stage IIIb (n = 2) and stage IV (n = 1).After the
first operation, 65 lung cancer patients had 4 cycles
chemotherapy, 6 patients had the radiotherapy and
4 patients had both.
The median interval between the primary operation
and CP was 24.4 months (1.5—145 m).Table 1 Indications for the primary operation and for CP
Indicationfor the
primary operation
No. Indication for CP No
Non-small cell lung cancer 88 Second primary lung cancer 51
Local metastasis 37
Tuberculosis 3 Lung metastasis 4
Bronchiectasis 1The indications for CP are showed in Table 1. The 88
patients with non-small cell lung cancer before were
performed CP for: second primary lung cancer (n = 51)
and local metastasis (n = 37). The 4 patients for the
benign disease as the indications for the primary oper-
ation were performed CP for lung metastasis and they
all had radical surgery before: breast cancer (n = 2), rec-
tal cancer (n = 1) and endometrial cancer (n = 1).
Before CP, careful preoperative evaluation included
assessment of the respiratory, cardiac and renal function.
The patients was considered suitable for completion
pneumonectomy if they had a predicted post-operative
forced expiratory volume in 1 s (FEV1) of more than 1 l/s,
estimated by spirometry exam and lung perfusion scan.
Renal failure was considered as the contraindication.
All the patients were checked by chest CT scan, tech-
netium bone scan and abdominal ultrasound. Mediasti-
noscopy was preformed when chest CT showed there
was any mediastinal node with a mean diameter wider
more than 1 cm in the recent 5 years. Bronchoscope
examination was a standard procedure for all these
patients. The above were used to evaluate if the patients
had resectable diseases and they did not have regional or
distant metastasis.
The postoperative TNM staging was: 4 Ia, 22 Ib, 3 IIa,
21 IIb, 30 IIIa, 7 IIIb, 5 IV (included 4 patients with lung
metastasis and 1 patient with brain metastasis).
The primary end points of analysis were morbidity and
mortality. The effect of risk factors on the end points
were evaluated with both univariate and multivariate
analysis. Risk factors represented by continuous variables
were assessed by use of 2-sample t tests when the
data were approximately normal and by rank sum tests
when the data were found to be not sufficiently Gaussian.
The effects of categorical variable risk factors were
evaluated by means of X2test and the Fisher exact
tests. Multiple logistic regression was used during multivari-
ate analysis to simultaneously evaluate the effect of risk
factors. P-value of the 0.05 or less was considered asSex ns ns
Older age (>65 years old ) 0.012 ns
Obesity 0.002 ns
CP at the right side ns ns
Hypertention ns ns
Diabets ns ns
Preoperative radiotherapy <0.001 ns
Preoperative chemotherapy ns ns
Table 3 Risk factors for the BPF
Risk factors BPF P value
Yes No
CP in the right side 7 54 ns
CP in the left side 1 30
Hand sutured 2 59 0.016
With mechanical stapler 6 25
Bronchial stump reinforcement 5 75 ns
Without reinforcement 3 9
Diabetes 2 8 ns
Without Diabets 6 76
Recurrence at the bronchial stump 1 24 ns
Not recurrence at the bronchial stump 7 60
Preoperative radiation or chemotherapy 6 77 ns
Without preoperative radiation or
chemotherpy
2 7
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COX regression were used to evaluate the survival of
the patients.
Follow-up was complete for all the patients in the group
and data were obtained from the follow-up secretary in
our department or from the government health agency.
Results
CP was performed through a standard posterolateral
approach with 5th rib removed not considering the pri-
mary incision. There was no intraoperative deaths. The









Figure 1 Survival time for stage I + II and stage III + IV lung cancer.CP performance was 1854.5 ml (200—9100 ml), 65
(70.6%) patients needed blood transfusion intra- or/ and
postoperation (4.5 unite; range 1—23 unite), 9 (9.78%)
patients died in the postoperative period: pulmonary
embolism (n = 2), DIC after the multisystem failure
(n = 1), respiratory failure after contralateral pneumonia
(n = 5), BPF with acute respiratory distress syndrome
(ARDS) (n = 1).
Factors associated with CP mortality in the univariate
analysis included (as shown in Table 2): older age
(>65 years ) (p = 0.012), obesity (p = 0.002) and preopera-
tive radiotherapy (p < 0.001). But in the multivariate
analysis, there were no any risk factor significantly asso-
ciated with CP mortality.
31(33.7%) patients had at least one major nonfatal
complication. These included respiratory insufficiency
(6, 6.5%), heart failure (2, 2.2%), cardiac arrhythmia
(12, 13.0%), hemorrhage necessitating reoperation (4, 4.3%),
bronchopleural fistula(8,8.7%), empyema (3,3.3%), myo-
cardial infarction(1,1.1%), sputum retention (6,6.5%),
stress ulceration (2,2.2%).
BPF occurred in 8(8.7%) patients in this group,.1
patient died of it after ARDS and the other 7 were trea-
ted successfully by a Clagett procedure. Table 3 shows
risk factors for the BPF.
All the CP patients were completely follow-up. Mean
follow-up time was 22.9 months (1-209 m). Actuarial 1-,
3- and 5 year survival rates from the time of CP were
81%, 26% and 14%. 5- year survival rates were sim-
ilar in the subgroup with second primary lung cancer ,




Table 4 Risk factors associated with the 5-year survival






Right or left side 0.031 ns
Older age(>65 years old) ns ns
T ns ns
N ns ns
TNM stage 0.010 0.008
Second primary lung cancer or
recurrence or lung metastases
ns ns
Bronchial stump cancer left ns ns
The interval between the primary
operation and CP
ns ns
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stage and III + IV stage in the 5-year survival rate
(20% vs 5%, P = 0.010, as shown in Figure 1). Risk factors
associate with the 5-year survival rates are shown in
the Table 4.
Discussion
Completion pneumonectomy is really a challenging proced-
ure for the thoracic surgeon. Sometimes it is really difficult
for the thoracic surgeon to decide if the patient would
benefit from the complex and dangerous procedure [5]. But
if the patient has the lung cancer recurrence, or second
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Nielsen [9] 1984 1974-82
McGovern [3] 1988 1958-85
Gregoire [10] 1993 1969-91
Terzi [11] 1994 1982-94
Massard [12] 1995 1978-82
AI-kattan [13] 1995 1980-93
Verhagen [14] 1996 1970-93
Regnard [15] 1999 1974-98
Fujimoto [1] 2001 1990-98
Miller [16] 2002 1985-98
Terzi [17] 2002 1982-2000
Guginno [18] 2004 1989-2002
Jungraithmayr [19] 2004 1986-2003
Chataigner [20] 2007 1996-2005
Current series 2008 1988-2007best choice for other treatments, such as chemotherapy
and radiotherapy, could not bring a long survival time.
Indication of CP for malignant lung disease includes
second primary lung cancer, local recurrence, recurrent
metastases from tumors in other systems or carcinomas
occurring after previous lobectomy for benign disease
[1]. In our study, we had not collect the last group
patients. Here, we are only interested in the result of CP
for the second time cancer operation for malignant dis-
ease to see in such condition if CP was worthwhile.
CP is associated with high mortality and mobidity,
which calls for careful planning before this procedure.
Careful assessment should be made to reconsider if the
patient has enough cardio-pulmonary reserve, the pa-
tient has a very good overall medical condition, and the
patient does not have regional or distant metastasis. In
the recent 5 years, in our department, repeat mediasti-
noscopy was sometimes used if the CT scan showed
there were lymphonodes with the diameter more than
1 cm. It is also recommended to have a close study of
the primary operation record: if the primary operation
was done extrapleurally, if azygos vein had been cut
down to explore the No 4 lymphonode, and how the
bronchus stump dealt with, et al., which will help us
to know what is the most difficulties in the following
CP procedure.
CP for lung metastases is rarely used and analysed. There
are only very limited data about CP for lung metastases.
Three major reservations against the use of extended
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with CP; A slightly improved long-term survival does not
justify the increased perioperative risk; Extrapulmonary
metastatic disease limited the long-term survival of
patients. In our study, there were only 4 patients with CP
for the lung metastases. It was too small number of the
patients to draw a conclusion from it.
Intro-or postoperative bleeding is a very common affair
for CP. In most series, the mean operative blood loss was
more than 1 L. Postoperative hemorrhage requiring reo-
peration also often happened. In our study, the mean op-
erative blood loss is 1854.3 l (200-9100 ml) and there were
4 postoperative hemorrhage requiring reoperation. It is
similar to some other series. Such bleeding may come from
taking down dense parietal adhesions or may originate from
the direct injuries to the heart or pulmonary blood vessels.
So it seems very important to get intrapericardial control of
the pulmonary blood vessels in the operation. If the pericar-
dial cavity is obliterated, one can divide the bronchus first,
followed by ligation of the pulmonary artery and vein.
Sometimes it is recommended to have mass closure of the
hilar vessels and bronchus with transhilar horizontal mat-
tress sutures, followed by oversewing of the vessels and
bronchus. Watanable suggested CP could be performed by
a median sternotomy. It was very easy to control the pul-
monary vessels in such condition to lower the risk of
hemorrhage. But on the other hand, it is really difficult to
free dense adhesions and to resect chest wall if required. In
our series, all the CP were performed through a standard
posterolateral approach with 5th rib removed not consider-
ing the primary incision.
For a majority of lung cancer patients who suffer from
a recurrent or second primary lung cancer, CP offers the
only chance for a cure. 5-year survival rate is one of the
most important factors to evaluate the long-term results
of CP. Compared with other articles, in our study the 5-
year survival rate is relatively lower (as shown in Table 5).
Maybe the following could explain it: In our study there
were more later stage lung cancer (III + IV stage)
patients who underwent CP procedure; All the patients
at least had 2 operations for the cure of malignant dis-
ease, so their real overall condition were not very good.Conclusions
In summary, mortality and morbidity of CP for lung cancer
are multifactorial and acceptable. Appropriate selection and
meticulous perioperative care are paramount to minimize
risk in those patients who require CP.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
All authors read and approved the final manuscript.Acknowledgements
This article was supported by Shanghai Municipal Health Bureau Youth Fund
(2012Y094); Wujieping Funding (320.6720.10003).
Received: 5 February 2012 Accepted: 23 September 2012
Published: 9 October 2012
References
1. Fujimoto T, Zaboura G, Fechner S, Hillejan L, Schroder T, Marra A, Krbek T,
Hinterthaner M, Greschuchna D, Stamatis G: Completion pneumonectomy:
current indications, complications, and results. J Thorac Cardiovasc Surg
2001, 121:484–490.
2. Bernard A, Deschamps C, Allen MS, Miller DL, Trastek VF, Gregory D,
Jenkins BS, Pairolero PC: Pneumonectomy for malignant disease: factors
affecting early morbidity and mortality. J Thorac Cardiovasc Surg 2001,
21:1076–1082.
3. McGovern EM, Trastek VF, Pairolero PC, Payne WS: Completion
pneumonectomy: indications, complications, and results. Ann Thorac Surg
1988, 46:141–146.
4. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW,
Ginsberg RJ: Incidence of local recurrence and second primary tumors in
resected stage I lung cancer. J Thorac Cardiovasc Surg 1995, 109:120–129.
5. Chu XH, Zhang X, Wang S, Lu XK, Wang XQ, Wang KJ: Clinical analysis of
completion pneumonectomy for pulmonary disease. Zhonghua Wai Ke Za
Zhi 2007, 45:1132–1135.
6. Grunenwald D, Spaggiari L, Girard P, Baldeyrou P, Filaire M, Dennewald G:
Completion pneumonectomy for lung metastases: is it justified? Eur J
Cardiothorac Surg 1997, 12:694–697.
7. Neptune WB, Woods FM, Overholt RH: Reoperation for bronchogenic
carcinoma. J Thorac Cardiovasc Surg, 52:342–350.
8. Mathisen DJ, Jensik RJ, Faber LP, Kittle CF: Survival following resection for
second and third primary lung cancers. J Thorac Cardiovasc Surg 1984,
88:502–510.
9. Nielsen OS, Boas J, Bertelsen S: Reoperation for recurrent bronchogenic
carcinoma. Scand J Thorac Cardiovasc Surg 1984, 18:249–250.
10. Gregoire J, Deslauriers J, Guojin L, Rouleau J: Indications, risks, and results
of completion pneumonectomy. J Thorac Cardiovasc Surg 1993,
105:918–924.
11. Terzi A, Lonardoni A, Falezza G, Scanagatta P, Santo A, Furlan G, Calabro F:
Completion pneumonectomy for non-small cell lung cancer: experience
with 59 cases. Eur J Cardiothorac Surg 2002, 22:30–34.
12. Massard G, Lyons G, Wihlm JM, Fernoux P, Dumont P, Kessler R, Roeslin N,
Morand G: Early and long-term results after completion
pneumonectomy. Ann Thorac Surg 1995, 59:196–200.
13. Al-Kattan K, Goldstraw P: Completion pneumonectomy: indications and
outcome. J Thorac Cardiovasc Surg 1995, 110:1125–1129.
14. Verhagen AF, Lacquet LK: Completion pneumonectomy. A retrospective
analysis of indications and results. Eur J Cardiothorac Surg 1996, 10:238–241.
15. Regnard JF, Icard P, Magdeleinat P, Jauffret B, Fares E, Levasseur P:
Completion pneumonectomy: experience in eighty patients. J Thorac
Cardiovasc Surg 1999, 117:1095–1101.
16. Miller DL, Deschamps C, Jenkins GD, Bernard A, Allen MS, Pairolero PC:
Completion pneumonectomy: factors affecting operative mortality and
cardiopulmonary morbidity. Ann Thorac Surg 2002, 74:876–883.
17. Tabutin M, Couraud S, Guibert B, Mulsant P, Souquet PJ, Tronc F:
Completion pneumonectomy in patients with cancer: postoperative
survival and mortality factors. J Thorac Oncol 2012, 7(10):1556–1562.
18. Guggino G, Doddoli C, Barlesi F, Acri P, Chetaille B, Thomas P, Giudicelli R,
Fuentes P: Completion pneumonectomy in cancer patients: experience
with 55 cases. Eur J Cardiothorac Surg 2004, 25:449–455.
19. Jungraithmayr W, Hasse J, Olschewski M, Stoelben E: Indications and results
of completion pneumonectomy. Eur J Cardiothorac Surg 2004, 26:189–196.
20. Chataigner O, Fadel E, Yildizeli B, Achir A, Mussot S, Fabre D, Mercier O,
Dartevelle PG: Factors affecting early and long-term outcomes after
completion pneumonectomy. Eur J Cardiothorac Surg 2008, 33:837–843.
doi:10.1186/1749-8090-7-107
Cite this article as: Zhang et al.: Completion pneumonectomy for lung
cancer treatment: early and long term outcomes. Journal of
Cardiothoracic Surgery 2012 7:107.
